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AIDSTrypanosoma cruzi (Chagas') encephalitis is an uncommonmanifestation of T. cruzi infection, typically seen in im-
munocompromised patients. Encephalitis results from the reactivation of chronic infection predominately in in-
dividuals from endemic areas. Increased awareness of this complication is essential especially with increased
migration of patients from endemic areas with concomitant HIV infection. Here we report a case of Chagas' en-
cephalitis in an AIDS patient fromMexico in which there was no evidence of acute serologic, CSF, or blood infec-
tion by T. cruzi trypomastigotes.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chagas' disease is a zoonosis caused by infection with the ﬂagellated
protozoan Trypanosoma cruzi. Chagas' disease is most common in south-
eastern Mexico, Central America, and South America. Cases reported in
theUnited States aremost often among immigrants from endemic coun-
tries, although vector-borne transmission in North America has been de-
scribed. Infection is primarily acquired via contact with the feces of the
triatomine insect. The insect nests in cracks and holes inside of homes
[1]. Transmission occurs when an infected vector contaminates the skin
ormucosa of a humanwith feces containing the trypomastigotes [2]. The
parasite enters the bloodstream when the host scratches the skin area
containing the insect feces. Less common means of transmission of the
parasite include blood transfusion, organ transplantation, and vertical
transmission from mother to infant [3]. In endemic areas, infection can
be prevented by assuring proper housing structure, avoiding cracks in
house structures, use of repellant, or insecticide-treated bed nets, and
screening of tissue and blood products for the parasite [2].
Acute T. cruzi infection may be associated with fever or swelling at the
inoculation site (chagoma). Early infection may be asymptomatic. Acutehomas Jefferson University, 280
107, USA.
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then proceed to a phase of illness deﬁned as the “chronic indeterminate”
phase. During this phase, patients are asymptomatic with little or no evi-
dence of parasitemia. The organisms can remain dormant for many years.
Only 20–30% of infected individuals suffer long-term sequelae of infection
[1]. The most common manifestations of chronic infection include gastric
motility disorders such asmegaesophagus andmegacolon, andcardiac con-
ditions such as dilated cardiomyopathy and conduction abnormalities [1,2].
The reactivation of chronic stages of disease is uncommon. Patients
at greatest risk for reactivation include those with cellular immunity
disorders such as acquired immunodeﬁciency syndrome (AIDS), leuke-
mia, and transplantation [3]. Cerebral tumors or chagomas caused by
T. cruzi is an uncommon complication of Chagas' disease, observed
only in immunosuppressed patients [3]. Individuals with advanced
HIV diseasewhohave spent signiﬁcant time living in areas of high ende-
micity of T. cruzi are at risk for the reactivation of Chagas' disease. Those
with CD4+ cell counts b200 cells/mm3 are also at increased risk of re-
activation [3]. Such individuals may presentwithmeningitis or focal ce-
rebral chagoma, which may be indistinguishable from toxoplasmosis,
tuberculosis, or a neoplastic process such as lymphoma.2. Case report
A 47-year-old Mexican male with a history of alcohol and intrave-
nous drug abuse presented to an outside hospital with right arm andr the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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with a CD4 count of 18 cells/mm3 and HIV viral load of 224,586
copies/mL. This low CD4 count together with evidence of HIV infection
qualiﬁed him for a diagnosis of AIDS. He had not received HAART ther-
apy. Theneurological symptomswere thought to representHIVneurop-
athy. During his hospitalization, his weakness progressed rapidly with
strength of 0/5 in the right upper extremity and 3/5 in bilateral lower
extremities. Initial MRI performed at an outside institution demonstrat-
ed a left frontal craniotomywith a small resection cavity in the left fron-
tal lobe. Therewas a dominantmass in the left frontal lobewhitematter
demonstrating ill-deﬁned nodular and peripheral enhancement with
surrounding vasogenic edema. There were small areas of diffusion re-
striction. A smaller lesion was present in the left aspect of the mid-
brain–pons junction. The patient stated the craniotomy was the result
of an accident that necessitated a neurosurgical procedure 8 years
prior to admission.
Based on the imaging ﬁndings and the patient's CD4 count, he was
empirically treated for Toxoplasmosis with pyrimethamine and
clindamycin. However, after approximately 9 days of empiric therapy
for presumed toxoplasmosis, he did not show any clinical improvement
and subsequent brain MRI showed progression in size and the number
of supratentorial lesions. At this point, hewas transferred to Thomas Jef-
ferson University for brain biopsy and further management.
Upon admission, the patient was in no apparent distress and com-
municative. Hismusculoskeletal and neurological examination revealed
an alert, awake male, oriented only to person, unable to spell words
frontward or backward, and somewhat inattentive. Cranial nerves II
through XII were grossly intact. Examination revealed left upper ex-
tremity dysmetria on ﬁnger-to-nose test. Deep tendon reﬂexes were
2+ and symmetric in the upper and lower extremities bilaterally,
with down-going toes bilaterally. Strengthwasworsening (0/5 strength
in the right upper and lower extremities, both distally and proximally;
5/5 strength in the left upper extremity, both distally and proximally,
and 0/5 on the left lower extremity, both distally and proximally). Sen-
sory examination was abnormal to all modalities and decreased in the
right upper and bilateral lower extremities throughout. A lumbar punc-
ture revealed red blood cell count of 5 cells/μL, white blood cell count of
2 cells/μL, elevated CSF protein (141mg/dL, normal range 15–55mg/dL)
with decreased glucose (29 mg/dL; normal range 40–70 mg/dL) with
oligoclonal bands (N5 IgG), and elevated myelin basic protein (15.4
mcg/L, abnormal: N 6.0 mcg/L). He was found to be neutropenic during
his hospital stay, attributable to HIV/AIDS. A CSF Toxoplasma gondii
quantitative PCR test was negative. He had positive Toxoplasma IgG,
and he continued to receive empiric therapy for presumed toxoplasma
encephalitis, with a regimen of pyrimethamine, sulfadiazine, and
leucovorin. Additionally, he was started on Vancomycin, ceftriaxone,
and metronidazole for a presumptive intracranial abscess. Testing for
the following infectious agents were negative in the CSF: cryptococcal
antigen, EBV quantitative DNA PCR, herpes simplex virus, types I and
II DNA, syphilis antibody, and JC polyoma virus DNA quantitative PCR.
Serology was negative for active infection with syphilis, hepatitis A
(IgM negative), or hepatitis C (negative HCV antibody, negative HCV
RNA PCR). Hepatitis B core antibody and hepatitis B surface antibody
were positive although HBV surface antigen was negative. On hospital
day 7, he was started on antiretroviral therapy. After 15 days of antire-
troviral therapy, HIV viral load declined to 806 copies/mL.
A follow-upMRI performed at our institution showed an increase in
size and surrounding edema of the lesions, as well as interval hemor-
rhage (Fig. 1). A cervical spine MRI with contrast (not shown) was ob-
tained and did not demonstrate any abnormality other than mild
degenerative changes. There were multiple, irregularly enhancing
masses with areas of diffusion restriction and hemorrhage involving
the supratentorial and infratentorial compartments. The differential di-
agnosis before biopsy included Toxoplasmosis and CNS lymphoma.
The patient's neurologic condition continued to deteriorate to the
point that he could not provide consent for brain biopsy. Due to thePlease cite this article as: D. Alyemni, et al., Histopathologic identiﬁcation o
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timately obtained and an open biopsy was performed on the 17th day
following admission to our hospital. The biopsy specimen demonstrated
a conﬂuent lymphohistiocytic inﬁltrate with plasma cells and some
neutrophils within central nervous system tissue. There were areas of
reactive gliosis and foci of necrosis. Scattered throughout were individ-
ual and clusters of small protozoal organisms (Fig. 2A). Individual or-
ganisms measured 1–3 μm in greatest dimension. The larger clusters
resembled bradyzoites of Toxoplasmosis (Fig. 2B). Well-preserved or-
ganisms contained a round nucleus with an adjacent rectangular bar
of chromatin consistent with a kinetoplast. There was minimal cyto-
plasm. Immunohistochemistry for toxoplasmosis (performed by Inte-
grated Oncology, New York, New York) was negative.
Based on the histopathologic ﬁndings and the patient demographics
(recently emigrated from Mexico), the differential diagnosis included
kinetoplastids such as T. cruzi and Leishmaniasis. Therefore, formalin-
ﬁxed parafﬁn-embedded tissuewas sent to the Centers for Disease Con-
trol (CDC) where PCR analysis positively conﬁrmed the presence of
T. cruzi. While awaiting the results, the patient was continued on thera-
py for possible Toxoplasma infection. He was brieﬂy treated with intra-
venous amphotericin due to concern for possible Leishmania infection.
Serum T. cruzi antibody testing sent to the CDCwas negative. Following
CDC Investigational New Drug (IND) Protocol no. 5765.0, benznidazole
was provided by the CDC for treatment of Chagas' disease. He received a
total course of 17-day therapy with benznidazole. Concurrent steroid
therapy was used. His course was complicated by transaminitis, neces-
sitating brief interruption of benznidazole therapy. Over the course of
his treatment, the patient's respiratory and hemodynamic status greatly
deteriorated, with concern for increased intracranial pressure and sei-
zures, possibly secondary to the initiation of antiprotozoal treatment
and possibly due to immune reconstitution syndrome secondary to ini-
tiation of HAART therapy. The patient remained in a minimally respon-
sive state with a stable neurologic exam and expired on the 50th
hospital day.
The brain autopsy showed an area of extensive necrosis involving
the left cerebral hemisphere, left basal ganglia, pons, and medulla mea-
suring 8 × 4 × 4 cm. There were numerous macrophages with rare
degenerated amastigotes. No viable organisms were identiﬁed. The
right basal ganglia/thalamic lesion seen onMRI showed similar ﬁndings
and accounts clinically for the patient's left-sided motor and sensory
deﬁcits. The systemic autopsy revealed no evidence of Chaga's disease
in any other organ. There was acute bronchopneumonia positive for
Cytomegalovirus.3. Discussion
The deﬁnitive diagnosis of T. cruzimeningoencephalitis or chagomas
in HIV patients is often challenging. Trypomastigotes can sometimes be
visualized on the microscopic examination of cerebral spinal ﬂuid [3,4].
Serologic testing is available, although cases of conﬁrmed central ner-
vous system Chagas' disease among individuals with negative serologic
testing for T. cruzi have been described [3,4]. Negative serology for
T. cruzi does not exclude the possibility of Chagas' central nervous sys-
tem disease. Indeed, our patient did not have evidence of trypanosomes
in the blood and was serologically negative for T. cruzi.
Brain lesions caused by the reactivation of T. cruzi can have a variable
radiographic appearance and have been described as single or multiple
lesions, with edema and contrast-enhancement [3]. In two series com-
prising a total of 25 patients with HIV/AIDS, most of the lesions were
supratentorial in location [4,7]. The majority of lesions in one of these
series demonstrated enhancement with white matter involvement [7].
Enhancing intramedullary spinal cord lesions have also been reported
[8]. The MRI spectroscopy of Chagas' lesions consists of a non-speciﬁc
pattern of increased choline, decreased or absent N-acetylaspartate,
and a lactate peak [6]. In summary, theMRI ﬁndings of cerebral Chagas'f Trypanosoma cruzi (Chagas') encephalitis in an AIDS patient, Human
Fig. 1.MRI of brain 34 days after initial presentation. (A and B) FLAIR exhibits increased mass effect and edema in the left frontotemporal region, involvement of the left basal ganglia
(arrow) and right basal ganglia (arrowhead). Increased edema surrounding the midbrain/pons lesion (minus). (C) Contrast-enhanced coronal T1-weighted image demonstrates nodular
and irregular enhancement in the left frontal lobe white matter, left basal ganglia, midbrain and pons (arrow). (D) Gradient echo image shows areas of low signal corresponding to hem-
orrhage (arrow).
3D. Alyemni et al. / Human Pathology: Case Reports xxx (2016) xxx–xxxdisease are non-speciﬁc and demonstrate features of both lymphoma
and Toxoplasmosis.
Macroscopic brain autopsy ﬁndings take the form of an extensive
necrotizing encephalitis. The majority of CNS Chagas' patients have
the pseudotumoral form, characterized by the presence of single or
multiple necrotic-hemorrhagic nodular lesions that are predominantly
located in the cerebral lobes. In some cases, the lesions involve the
brain stem and cerebellum. The lesions are poorly demarcated,Fig. 2. Biopsy of Brain lesion. (A) Small clusters of protozoal organisms within a background
Bradyzoite-like cluster of protozoans with kinetoplasts (enlarged inset). Hematoxylin and eosi
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the white matter [9].
The histologic picture of CNS Chagas' is an acute necro-hemorrhagic
encephalitis, characterized by microglial nodules, with associated hemor-
rhage, necrosis, and exudates of lymphocytes, macrophages, plasma cells,
and occasionally neutrophilic granulocytes within the nervous tissue and
perivascular spaces [9]. The parasites exist in abundance within macro-
phages and astroglia in the amastigote forms but are not found in neurons.lymphohistiocytic inﬁltrate (hematoxylin and eosin, original magniﬁcation 400×). (B)
n, original magniﬁcation 1000×. N, nucleus; K, kinetoplast.
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by PCR. Lymphoplasmacytic leptomeningitis is a constant ﬁnding in CNS
Chagas' and thought to represent an extension of the subjacent necrotic-
inﬂammatory lesions [9]. Histologically, the differential diagnosis of
T. cruzi includes other protozoal infections such as Toxoplasmosis, Leish-
mania, and other trypanosome species. The key feature to recognize is
the presence of the kinetoplast. Kinetoplasts are mitochondrial DNA that
appears as a bar just above the nucleus (Fig. 2B) and can only be appreci-
ated in well-preserved amastigotes at high magniﬁcation (400–1,000×).
The kinetoplast resembles an eyebrow over the nucleus.
Primary prophylaxis with antiparasitic medication may prevent re-
activation in immunocompromised individuals. HIV-infected individ-
uals with epidemiologic risk factors for T. cruzi exposure should be
tested for latent infection via serology. Such patients who test positive
and have no symptoms of Chagas' disease may beneﬁt from a single
course of primary prophylaxiswith an antiparasitic agent (benznidazole
or nifurtimox) [5]. Additionally, initiation of antiretroviral therapy may
prevent the reactivation of Chagas' disease [5].
The reactivation of Chagas' disease is severe in AIDS patients. While
there are diagnostic challenges in regard to cerebral T. cruzi in AIDS pa-
tients, it is important to consider the diagnosis in individuals who are
failing to respond to therapy for toxoplasmosis and who have epidemi-
ologic risk for Chagas' disease. If cerebral Chagas' is not considered in thePlease cite this article as: D. Alyemni, et al., Histopathologic identiﬁcation o
Path Case Reports (2016), http://dx.doi.org/10.1016/j.ehpc.2016.06.002differential diagnosis, the diagnosis is often made late in the clinical
course. Delay in accurate diagnosis can lead to life threatening events
and signiﬁcant mortality [3].References
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